-Livemint.com India’s new industrial policy is an opportunity to address the problems of low R&D spending and tough competition from cheap Chinese imports The framing of the new industrial policy should be seen as an opportunity to chart a meaningful path for industry’s role in India’s development. The recently released discussion paper by the department of industrial policy and promotion mentions two points that need to be examined closely to grasp the...

-TheWire.in The government’s premier policy-formulating agency recently recommended measures to deregulate the pharmaceutical sector and make essential medicines more expensive. New Delhi: Even as the prime minister repeatedly expresses his commitment to providing affordable medicines in the country, it appears that the NITI Aayog and the Department of Pharmaceuticals (DoP) may be working in an opposing direction. Documents between October 2016 and April 2017 show the intention of various government arms to...

-The Times of India NEW DELHI: The government has invoked special powers under the law to prohibit stent makers from withdrawing their products from the market for the next six months. Amid reports that several manufacturers, including Abbott and Medtronic, are seeking to withdraw premium, high-priced stents from the Indian market on account of the price cap imposed by National Pharmaceutical Pricing Authority (NPPA), the government has directed companies to maintain production,...

-The Telegraph New Delhi: Regulatory efforts to get doctors in India to prescribe medicines only through their generic names, initiated about 15 years ago, will need to overcome legal challenges and resistance from sections of doctors and the pharmaceutical industry, experts said. Senior pharmacologists and industry analysts have also said it will be misleading to presume that prescriptions with generic names will automatically translate into lower medicine bills for patients as studies...

-The Hindu New Delhi: Days after it was revealed that the Centre is likely to dismantle the National Pharmaceutical Pricing Agency (NPPA), its chairman said the decision was ‘rushed’ and the agency was not consulted. “There were two meetings and the NPPA was not a party to them. Both meetings were held at short notice. This has been a rushed decision. For any policy change, there needs to be consultation. I understand...